BioCentury | Sep 15, 2020

Sept. 14 Quick Takes: $70M+ rounds for Escient, Escape, plus Alzheimer’s data lifts Cassava shares and more

Escient raises $77.5M B roundEscient Pharmaceuticals Inc. announced Monday the start of a Phase I/Ib trial of lead program EP547 for cholestatic and uremic pruritis alongside a $77.5 million series B round led by Sanofi...
BioCentury | Jul 29, 2020
Distillery Therapeutics

Promoting degradation of the MDM2 oncogene for liposarcoma

DISEASE CATEGORY: Cancer INDICATION: Sarcoma A pyrido-indole-based tool compound that triggers degradation of MDM2, an enzyme that suppresses p53 expression, could treat liposarcoma. In 10 human liposarcoma cell lines, the compound inhibited growth with IC...
BioCentury | Jun 19, 2020
Product Development

InflaRx, Kiniksa anti-inflammatory mAbs yield trend toward lower COVID-19 mortality, plus Sinopharm reports antibody readout from vaccine trial

After dexamethasone set a new bar for mortality reduction in COVID-19 patients this week, InflaRx and Kiniksa reported data from their anti-inflammatory mAbs showing trends toward a survival benefit. InflaRx N.V. (NASDAQ:IFRX) announced on Wednesday...
BioCentury | Apr 3, 2020

Oncology company Zentalis posts double-digit gain after pricing upsized IPO

For the handful of biotechs waiting in the IPO queue, Zentalis’ upsized offering and early aftermarket performance offer encouraging signs that the public markets remain receptive to new biopharma listings, even amid weeks of uncertainty...
BioCentury | Mar 4, 2020

March 3 Quick Takes: Megarounds for Akouos, Element; plus venture rounds by Kahr, Primmune, Lipidio and Scipio and more

Pivotal bioVentures, crossovers back Akouos in $105M series B Akouos Inc., a gene therapy company developing treatments for hearing loss, raised $105 million in a series B round led by Pivotal bioVentures. New investors included...
BioCentury | Jan 11, 2020
Company News

Led by Blatt, Aligos reunites Alios team to develop functional cure for HBV

Led by a team of veterans from Alios BioPharma and Janssen, Aligos Therapeutics raised $125 million in a series B round to bring three of its HBV therapies to the clinic this year. Aligos thinks...
BioCentury | Dec 10, 2019
Emerging Company Profile

Zentalis debuts with trio of clinical oncology programs, $85M series C

Zentalis emerged from stealth Monday with an untranched and oversubscribed $85 million series C and three internally discovered clinical cancer candidates, with plans to begin pivotal testing by 2021. The C round syndicate includes Matrix...
BioCentury | Jul 25, 2019
Distillery Therapeutics

Inhibiting PARP for pathologic vascular calcification

DISEASE CATEGORY: Cardiovascular INDICATION: Cardiovascular PARP inhibition could treat pathologic vascular calcifications. In patients with carotid artery disease, sites of calcification within atherosclerotic plaques and blood vessel tunica media had higher extranuclear deposition of PARP-synthesized...
BioCentury | Apr 24, 2019
Financial News

Why Satsuma investors see room for another migraine therapy

While a new class of drugs has captured most of the attention around migraine treatments, Satsuma's investors believe there's room in the marketplace for a new formulation of an old drug. Satsuma Pharmaceuticals Inc. (South...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
Items per page:
1 - 10 of 286